Oprah Winfrey, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Oprah Winfrey, Maintenance, and What Happens If You Stop

Oprah's Public Disclosure: What She Actually Said

In a December 2023 People magazine cover story, Oprah Winfrey confirmed she had been using "a weight loss medication" she described as a GLP-1 receptor agonist. She did not name the specific drug in that initial disclosure. Reporting from multiple outlets, combined with the timing and her description of the medication's mechanism, has led to widespread public speculation that the drug is tirzepatide (brand name Mounjaro or Zepbound), though Oprah has not publicly confirmed the exact compound.

In March 2024, she hosted An Oprah Special: Shame, Blame and the Weight Loss Revolution on ABC, where she spoke with physicians, patients, and researchers about obesity as a chronic disease. She stated on camera that she viewed the medication as "a tool" and "a gift" after decades of public struggle with weight.

One month earlier, in February 2024, Oprah stepped down from the board of WeightWatchers (now WW International), citing a conflict of interest between her medication use and her role at a company that had historically marketed behavioral weight loss programs. She also donated her equity stake to the National Museum of African American History and Culture.

These disclosures remain among the most high-profile public confirmations of GLP-1 use by any public figure. Whether Oprah continues on the medication, has adjusted her dose, or has discontinued it is not part of the confirmed public record as of this writing.

How GLP-1 Receptor Agonists Work (Brief Primer)

GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and enhance glucose-dependent insulin secretion. Semaglutide (Wegovy, Ozempic) targets the GLP-1 receptor alone. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, which may partly explain its greater average weight reduction in head-to-head data.

Both drug classes produce clinically meaningful weight loss in the range of 15% to 22.5% of body weight at maximum doses in key trials. But the question Oprah's story raises for millions of patients is straightforward: what happens when you stop?

The Discontinuation Data: What Clinical Trials Show

At a glance

  • STEP 1 Extension Trial: Participants who stopped semaglutide 2.4 mg regained roughly two-thirds of lost weight within one year of discontinuation (Wilding et al., 2022, JAMA).
  • SURMOUNT-4: Tirzepatide patients randomized to placebo after 36 weeks of treatment regained approximately half of lost weight by week 88, while those continuing tirzepatide lost an additional 5.5% (Aronne et al., 2024, JAMA).
  • Metabolic parameters also rebound: Improvements in HbA1c, blood pressure, and lipid profiles partially reversed after discontinuation in both trials.
  • Appetite signaling returns: The suppression of hunger hormones (ghrelin normalization, reduced satiety signaling) reverses within weeks of stopping therapy.

The STEP 1 extension trial is the most cited discontinuation dataset for semaglutide. Participants lost an average of 17.3% of body weight over 68 weeks on semaglutide 2.4 mg. After switching to placebo, they regained 11.6 percentage points of that loss by week 120, retaining only about one-third of the original benefit (Wilding et al., 2022).

For tirzepatide, the SURMOUNT-4 trial used a withdrawal design. All participants received tirzepatide for 36 weeks (losing roughly 20.9% body weight on average), then were randomized to either continue or switch to placebo. The placebo group regained 14 percentage points over the next year. Those who continued lost an additional 5.5% (Aronne et al., 2024).

The pattern across both drugs is consistent. Obesity is a chronic condition driven by neurohormonal set points that medication temporarily overrides. When the medication is removed, those set points reassert themselves. This is not a failure of willpower. It is documented neurobiology.

Why Weight Regain Happens: The Biology Oprah Has Talked About

Oprah's public framing of obesity as a disease, not a character flaw, aligns with the position of the American Medical Association, the Endocrine Society, and the Obesity Medicine Association. The clinical rationale is well-established.

After weight loss (by any method), the body mounts a coordinated counter-regulatory response. Leptin levels drop. Ghrelin rises. Resting metabolic rate decreases beyond what lost tissue mass alone would predict, a phenomenon called metabolic adaptation or adaptive thermogenesis. Energy expenditure can remain suppressed for years. This was demonstrated dramatically in a study of Biggest Loser contestants who showed persistent metabolic suppression six years after their televised weight loss.

GLP-1 agonists work partly by overriding this counter-regulatory system. They suppress appetite at the hypothalamic level and modify reward-based eating behavior. When the drug is withdrawn, these compensatory mechanisms return to their pre-treatment state. The result is predictable weight regain, not because the patient "gave up," but because the biological drive to restore prior body mass is powerful and persistent.

Long-Term Use: What the Evidence Supports

Given the discontinuation data, most obesity medicine specialists now frame GLP-1 therapy as a chronic treatment, similar to statins for hyperlipidemia or antihypertensives for blood pressure.

The SELECT cardiovascular outcomes trial (semaglutide 2.4 mg, published in NEJM, 2023) demonstrated a 20% reduction in major adverse cardiovascular events over a median 39.8 months of treatment. This trial provided the strongest argument to date for sustained therapy in patients with obesity and established cardiovascular disease.

Long-term safety data beyond 4 to 5 years remains limited. Known side effects at maintenance doses include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), which typically attenuate over time. Rare but serious signals under ongoing surveillance include pancreatitis, gallbladder events, and a theoretical thyroid C-cell concern observed in rodent models but not confirmed in human epidemiological data. The FDA label for both semaglutide and tirzepatide carries a boxed warning regarding medullary thyroid carcinoma risk in patients with a personal or family history of MTC or MEN2.

Maintenance Strategies: Dose Reduction vs. Full Discontinuation

A clinical question that Oprah's journey raises (without answering publicly) is whether dose reduction can preserve benefits while minimizing side effects and cost.

Preliminary data suggest that stepping down to a lower maintenance dose may retain some benefit compared to full discontinuation, though no large randomized trial has tested this head-to-head. In the STEP 5 trial, patients on semaglutide 2.4 mg maintained weight loss over two years of continuous therapy with a plateau effect, suggesting the drug sustains rather than progressively deepens weight loss.

The HealthRX Medical Team notes that current clinical practice often involves:

  1. Continued full-dose therapy for patients tolerating the medication well and deriving cardiovascular or metabolic benefit.
  2. Dose reduction trials in which the patient steps down one dose tier with close monitoring of weight trajectory and metabolic markers over 3 to 6 months.
  3. Structured discontinuation with behavioral and dietary support, understanding that most patients will regain weight and may need to restart.
  4. Combination approaches pairing a reduced GLP-1 dose with structured resistance training to preserve lean mass, a strategy with biological plausibility but limited controlled trial data.

No consensus guideline yet dictates which patients should attempt discontinuation versus remain on lifelong therapy. The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends ongoing treatment for patients who respond, acknowledging the chronic nature of the disease.

The HealthRX Medical Team Take

Oprah Winfrey's disclosure did something clinical trials cannot: it gave tens of millions of people permission to view obesity treatment as medicine rather than moral failure. Her decision to leave the WeightWatchers board underscored the tension between behavioral-only approaches and pharmacotherapy in a way no journal editorial could match.

From a clinical standpoint, the data are clear. Stopping a GLP-1 agonist without a structured transition plan will, for most patients, result in substantial weight regain within 12 months. This is not controversial. It is the expected pharmacological outcome of discontinuing a drug that modifies central appetite regulation.

The harder question, one that neither Oprah nor current evidence can fully answer, is how long is long enough. Four-year cardiovascular outcome data from SELECT supports sustained use. But lifetime use beginning in a patient's 40s or 50s means decades of exposure for which safety data does not yet exist. Patients and clinicians are making a reasonable bet, not following a fully mapped road.

For patients considering discontinuation, the HealthRX Medical Team recommends doing so only under medical supervision, with baseline metabolic labs (fasting glucose, HbA1c, lipid panel, liver enzymes), a tapering plan rather than abrupt cessation, and realistic expectations grounded in the STEP 1 and SURMOUNT-4 withdrawal data.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. JAMA. 2022;327(14):1348-1360. https://jamanetwork.com/journals/jama/fullarticle/2799085
  • Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
  • Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
  • Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after The Biggest Loser competition. Obesity. 2016;24(8):1612-1619. https://pubmed.ncbi.nlm.nih.gov/27136388/
  • Kadowaki T, Isendahl J, Weghuber D, et al. Semaglutide once-weekly in adults with overweight or obesity, with or without type 2 diabetes (STEP 5). Diabetes Obes Metab. 2022;24(12):2398-2409. https://pubmed.ncbi.nlm.nih.gov/36356054/
  • Halpern B, Mancini MC. GLP-1 receptor agonists and pancreatitis risk. Lancet Diabetes Endocrinol. 2023. https://pubmed.ncbi.nlm.nih.gov/36455513/
  • Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(3):e1163-e1192. https://academic.oup.com/jcem/article/109/3/e1163/7471661